Kisho

Lawrence Panasci, MD — Rare Disease Pipeline | Kisho

Lawrence Panasci, MD

Other

Orphan Designations

0 approved, 1 designated

FDA Approvals

Active Trials

Rare Diseases

across 8 areas

News (30d)

Quiet

Lawrence Panasci, MD is a company with 1 orphan drug designation across 3 rare diseases. 1 active policy bill affects their portfolio.

Competitive Landscape

Diversified Portfolio

Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.

Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA

Approved: 0

In Trials: 0

Designated Only: 3

3 total diseases

Disease	Drug(s)	Stage
malignant carotid body paraganglioma	2-chloroethyl-3-sarcosinamide-1-nitrosourea	Des.TrialAppr.
post-treatment Lyme disease syndrome	2-chloroethyl-3-sarcosinamide-1-nitrosourea	Des.TrialAppr.
treatment-refractory schizophrenia	2-chloroethyl-3-sarcosinamide-1-nitrosourea	Des.TrialAppr.